CBAY News and Press, CymaBay Therapeutics Inc. From 08/28/23

NEWARK, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the grant of inducement awards to three employees betw...

2023-08-14 16:31:43 ET UBS has initiated coverage of Cymabay Therapeutics ( NASDAQ: CBAY ) with a buy rating, stating it sees a Phase 3 study for the company’s drug seladelpar in the treatment of primary biliary cholangitis, or PBC, yielding positive data. UBS said it exp...

2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...

Shares of CymaBay Therapeutics, Inc. (NASDAQ: CBAY) traded at a new 52-week high today and are currently trading at $13.38. So far today, approximately 542.63k shares have been exchanged, as compared to an average 30-day volume of 2.48M shares. CymaBay Therapeutics, Inc., a clinical-stage bio...

2023-08-10 21:54:06 ET CymaBay Therapeutics, Inc. (CBAY) Q2 2023 Earnings Conference Call August 10, 2023, 04:30 PM ET Company Participants Paul Quinlan - General Counsel Sujal Shah - President and Chief Executive Officer Harish Shantharam - Chief Financial Offic...

2023-08-10 16:05:57 ET CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q2 GAAP EPS of -$0.01 beats by $0.22 . Revenue of $31.01M. Collaboration revenue recognized for the three and six months ended June 30, 2023 was $31.0 million, on completion of the initial ...

Top-line data from RESPONSE Phase 3 study in PBC expected by end of September 2023 IDEAL clinical trial actively recruiting Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clin...

CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase PR Newswire Evaluates seladelpar 10 mg vs. placebo for alkaline phosphatase normalization at...

NEWARK, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that it will host a conference call and live audio web...

2023-07-20 06:50:16 ET Summary CymaBay Therapeutics' primary candidate, seladelpar, shows promising results as a potential treatment for primary biliary cholangitis, a liver autoimmune disease. Seladelpar demonstrated significant anti-cholestatic, anti-inflammatory, and anti-pruri...